A major drug maker has joined President Trump’s effort to steady the price of medical drugs in an effort to curtail rising healthcare costs. The Washington Examiner reports:
Drug maker Amgen, which recently said that it won’t raise prices again this year, is crediting the Trump administration’s effort to steady the price of drugs.
In a transcript of the company’s earnings call, Amgen Chairman and CEO Robert A. Bradway said, “We appreciate the administration’s engagement on this important issue. As to prices, we made the decision a few months ago not to increase the prices of any of our medicines at mid-year. And we have no plans to change that through the balance of the year.”
The president has pushed companies to lower prices and promised that many would. Amgen is one of the biggest to act since Trump made his promise. Alex Azar, his Health and Human Services Department secretary, recently testified in Congress that companies will announce price freezes after second quarter reports.
The move by Amgen, one of the world’s biggest, came after it reported a better-than-expected second quarter profit.
This comes as a huge boost to President Trump’s healthcare agenda.